|
|
||||||||



*
Laboratory of Immunology, National Heart, Lung, and Blood Institute, and
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
To further characterize the development of mast cells from human hemopoietic pluripotent cells we have investigated the expression of telomerase activity in cultured human peripheral blood CD34+ cells, and CD34+/CD117+/CD13+ progenitor mast cells selected therefrom, with the idea that induction of telomerase is associated with clonal expansion of CD34+/CD117+/CD13+ cells. A rapid increase in telomerase activity preceded proliferation of both populations of cells in the presence of stem cell factor and either IL-3 or IL-6. The induction was transient, and telomerase activity declined to basal levels well before the appearance of mature mast cells. Studies with pharmacologic inhibitors suggested that this induction was initially dependent on the p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase, but once cell replication was underway telomerase activity, but not cell replication, became resistant to the effects of inhibitors. Tumor mast cell lines, in contrast, expressed persistently high telomerase activity throughout the cell cycle, and this expression was unaffected by inhibitors of all known signaling pathways in mast cells even when cell proliferation was blocked for extended periods. These results suggest that the transient induction of telomerase activity in human progenitor mast cells was initially dependent on growth factor-mediated signals, whereas maintenance of high activity in tumor mast cell lines was not dependent on intracellular signals or cell replication.
This article has been cited by other articles:
![]() |
A. Ujike-Asai, A. Okada, Y. Du, M. Maruyama, X. Yuan, F. Ishikawa, Y. Motoo, K. Isobe, and H. Nakajima Large defects of type I allergic response in telomerase reverse transcriptase knockout mice J. Leukoc. Biol., August 1, 2007; 82(2): 429 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Kushnir-Sukhov, A. M. Gilfillan, J. W. Coleman, J. M. Brown, S. Bruening, M. Toth, and D. D. Metcalfe 5-Hydroxytryptamine Induces Mast Cell Adhesion and Migration J. Immunol., November 1, 2006; 177(9): 6422 - 6432. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Iwaki, C. Tkaczyk, A. B. Satterthwaite, K. Halcomb, M. A. Beaven, D. D. Metcalfe, and A. M. Gilfillan Btk Plays a Crucial Role in the Amplification of Fc{epsilon}RI-mediated Mast Cell Activation by Kit J. Biol. Chem., December 2, 2005; 280(48): 40261 - 40270. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Hundley, A. M. Gilfillan, C. Tkaczyk, M. V. Andrade, D. D. Metcalfe, and M. A. Beaven Kit and Fc{epsilon}RI mediate unique and convergent signals for release of inflammatory mediators from human mast cells Blood, October 15, 2004; 104(8): 2410 - 2417. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tkaczyk, V. Horejsi, S. Iwaki, P. Draber, L. E. Samelson, A. B. Satterthwaite, D.-H. Nahm, D. D. Metcalfe, and A. M. Gilfillan NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc{epsilon}RI aggregation Blood, July 1, 2004; 104(1): 207 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tkaczyk, M. A. Beaven, S. M. Brachman, D. D. Metcalfe, and A. M. Gilfillan The Phospholipase C{gamma}1-dependent Pathway of Fc{epsilon}RI-mediated Mast Cell Activation Is Regulated Independently of Phosphatidylinositol 3-Kinase J. Biol. Chem., November 28, 2003; 278(48): 48474 - 48484. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ping, A. Asai, A. Okada, K. Isobe, and H. Nakajima Dramatic increase of telomerase activity during dendritic cell differentiation and maturation J. Leukoc. Biol., August 1, 2003; 74(2): 270 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
N.-p. Weng Interplay between telomere length and telomerase in human leukocyte differentiation and aging J. Leukoc. Biol., December 1, 2001; 70(6): 861 - 867. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |